Navigating UK Pharmacovigilance Requirements for Natural Health Products: A Comprehensive Guide for Canadian Manufacturers

The UK dietary supplements market was valued at approximately USD 4.79 billion in 2024 and is projected to reach nearly USD 9.65 billion by 2033, growing at around 8.1% annually. A sophisticated, health-conscious consumer base, with the most positive attitude toward supplements in Europe, makes the UK genuinely compelling for Canadian NHP manufacturers looking beyond North America.

But Brexit fundamentally restructured how natural health products are regulated in Great Britain (England, Scotland, and Wales). Since January 2021, the UK operates under its own independent regulatory framework, its own ingredient lists, its own health claims register, its own pharmacovigilance infrastructure, and its own local representation requirements. Products compliant with EU law are not automatically compliant in Great Britain. EU approvals and Canadian NHP licences do not transfer.

The export of natural health products (NHPs) from Canada to the United Kingdom presents a complex regulatory challenge, particularly in the domain of pharmacovigilance (PV). The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) enforces a rigorous and evolving framework to ensure the safety, efficacy, and quality of NHPs. For Canadian manufacturers accustomed to Health Canada’s regulatory environment, understanding the nuances of the UK’s PV requirements is essential to achieve compliance and successfully market products in the UK

The UK Regulatory Framework for Natural Health Products

Unlike in Canada, where Health Canada holds primary NHP authority, the UK distributes regulatory responsibility across three bodies, and compliance with one does not guarantee clearance from the others.

The MHRA (Medicines and Healthcare products Regulatory Agency) regulates all licensed medicinal products, including Traditional Herbal Registrations (THRs). It manages pharmacovigilance obligations under the Human Medicines Regulations 2012, oversees the borderline classification process for products that may be either food or medicine, and operates the Yellow Card scheme, the UK's national adverse reaction reporting system. In January 2025, the MHRA published updated Good Pharmacovigilance Practices (GVP) that now meaningfully diverge from EU standards, including UK-specific Risk Management Plans, PSUR timelines, and an independently maintained Pharmacovigilance System Master File.

The FSA (Food Standards Agency) governs food supplements, novel food applications, and permitted ingredient lists in England, Wales, and Northern Ireland. Local Trading Standards authorities enforce food labelling and health claims compliance at retail.

The DHSC (Department of Health and Social Care) oversees the Nutrition and Health Claims framework.

A Canadian NHP can simultaneously attract MHRA scrutiny (if its claims lean medicinal), FSA action (if it contains a novel ingredient), and Trading Standards enforcement (if the label uses an unapproved health claim). Managing all three is not optional; it's the baseline.

Classification: The Decision That Shapes Every Obligation

Product classification is one of the most consequential decisions in a UK market entry strategy. Three pathways are most relevant to Canadian manufacturers:

Food Supplements

Most vitamins, minerals, and botanical products marketed without medicinal claims will qualify as food supplements, no pre-market registration required. But compliance is not automatic. Post-Brexit, Great Britain independently determines which ingredients are permitted, and health claims are only lawful if they appear on the Great Britain Nutrition and Health Claims Register. EU-approved claims that were not explicitly adopted into GB law post-Brexit are not permitted.

Traditional Herbal Medicinal Products (THMPs), the THR Pathway

Products making therapeutic claims for minor health conditions that don't require medical supervision can be registered under the Traditional Herbal Registration (THR) scheme. Requirements include 30 years of traditional use (at least 15 years in the EU/EEA, or in countries with equivalent pharmacovigilance systems for GB-only registrations), GMP compliance, and a product-level safety assessment. The THR certification mark is well-recognized by UK consumers and provides meaningful market credibility.

THR holders carry full medicinal pharmacovigilance obligations, including adverse event reporting to the MHRA, PSUR submissions, a UK QPPV, and a PSMF.

Full Marketing Authorization (MA)

Products with strong therapeutic claims, or whose ingredients place them within the definition of a medicinal product under the Human Medicines Regulations 2012, require a full MA from the MHRA, assessed within 210 days. An MA triggers the most comprehensive set of pharmacovigilance obligations. For most Canadian NHP manufacturers, the THR or food supplement pathway is more proportionate, but the MHRA's case-by-case borderline decisions can push a product toward MA territory unexpectedly.

Pharmacovigilance Requirements

For food supplements, formal pharmacovigilance reporting is not mandated, but proactive safety monitoring is expected as a standard of good practice. For THR and MA products, the obligations are substantive:

• Adverse Event Reporting: Submission of Individual Case Safety Reports (ICSRs) for all serious and non-serious adverse events occurring in the UK and serious events from other countries. For products marketed in Northern Ireland, reporting must also comply with EU requirements via Eudravigilance gov.uk.

• Signal Detection and Management: Manufacturers must maintain systems capable of detecting safety signals across all data sources and of notifying the MHRA within 3 working days of establishing that a signal meets the definition of an emerging safety issue. Signals must be validated and reported through variations, PSURs, or standalone notifications as appropriate.

• Risk Management Plans (RMPs): Submission of RMPs and updates whenever new safety data emerges, following EU templates with UK-specific annexes where applicable. Additional Risk Minimization Measures (aRMMs) require MHRA agreement before implementation.

• Periodic Safety Update Reports (PSURs): Regular submission of PSURs according to EU reference dates or UK-specific timelines, with detailed reporting on safety and benefit-risk evaluations.

• Post-Authorisation Safety Studies (PASS): Submission of protocols, amendments, and final reports for imposed or voluntary PASS, with strict timelines and fees depending on study type and regulatory status.

• Safety Referrals and Major Safety Reviews: Manufacturers must inform the MHRA of any new safety information and participate in safety reviews, which may lead to regulatory actions including labeling changes or product withdrawals.

• Post-Authorisation Measures (PAMs): Compliance with specific obligations and commitments imposed on marketing authorizations, including conditions and risk minimization activities.

Your Canadian Foundation Is a Head Start, If You Use It Right

Canadian NHP manufacturers with functioning compliance programs are not starting from scratch. Health Canada's GMP documentation, product safety assessments, Annual Summary Report process and structured SOPs are all direct inputs into a UK market entry package. Maintaining a robust Canadian safety monitoring system is putting your company one step ahead to accessing the UK market.

How VigiQuest Analytics Can Help

Whether you are scaling up from a startup with a single product or running a multinational with a complex portfolio targeting the UK Market, VigiQuest Analytics can assess your current pharmacovigilance posture and recommend the right path forward. Our pharmacovigilance and regulatory affairs practice supports NHP licensees with:

•  Compliance gap analyses and GVP inspection readiness assessments

• SOP development, Safety Data Exchange Agreement review, and PV staff training

• End-to-end adverse reaction case management and Annual Summary Report preparation

• Signal detection, benefit-risk evaluation, and Health Canada response support

• Strategic advice on the evolving NHP regulatory framework

 Schedule your free, no-obligation assessment today.

Resources

• Medicines and Healthcare products Regulatory Agency. Pharmacovigilance following agreement of the Windsor Framework. GOV.UK, August 2024. Updated February 2026.

• Medicines and Healthcare products Regulatory Agency. Apply for a traditional herbal registration (THR). GOV.UK, December 2014.

• Medicines and Healthcare products Regulatory Agency. Guidance on new provisions for traditional herbal medicinal products and homeopathic medicinal products. GOV.UK, December 2020.

• Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. GOV.UK, January 2021.

• Medicines and Healthcare products Regulatory Agency. Exceptions and modifications to the EU guidance on good pharmacovigilance practices that apply to UK marketing authorisation holders and the licensing authority. MHRA, 2025.

• Health Canada. Reporting adverse reactions to marketed health products: Guidance document for industry. Health Canada, November 2022. Updated February 2026.

• Health Canada. Site Licensing Guidance Document. Health Canada, November 2015.

• British Herbal Medicine Association. Legislation on herbal medicines. BHMA, 2026.